In addition, the combination treatment reduced the expression of mesenchymal markers (vimentin, N-calcium-adhesion protein, Slug, Snail, and MMP-9), but promoted the expression of epithelial marker E-calcium-adhesion protein, indicating that it may inhibit the cell migration of KRAS mutant CRC cells and inhibit EMT. This evidence concerns the gene KRAS and colorectal carcinoma.